InDex Pharmaceuticals Holding AB hosted a Capital Markets Day on March 14, 2022 for investors, analysts and media. 

The focus of the Capital Markets Day was the ongoing phase III study CONCLUDE with the drug candidate cobitolimod, cobitolimod’s market potential and InDex’s long-term strategies for commercialisation of cobitolimod. Cobitolimod is under development as a novel local treatment for moderate to severe ulcerative colitis. Cobitolimod has with a low dosing frequency shown a competitive efficacy and an excellent safety profile in previous clinical studies.

Presentations were given by members of InDex’s management and contracted experts in marketing and commercialisation. The program was closed with a Q&A session.

The Capital Markets Day was held in English and live streamed on